The results of its Phase 3 clinical trial, just released by the drugmaker, amply justify the buzz
The trials consisted of 162 women, aged 1865, and reported results that include: Clinical measurements: 26% increase in skin radiance after two months 40% increase in radiance after three months 65% improvement in skin uniformity after three months Consumer perception: 100% of participants showed increased skin radiance within two months Additionally, key ingredients have been shown to optimize antioxidant defenses and promote the skin's resilience to environmental stressors.* Be one of the first to try USANA's revolutionary Glow by visiting usana.com
Cross-border shipping: Retatrutide shipping from the US to Canada involves customs clearance, potential duties, and extended transit time
As of April 2026, the BPC-157 FDA approval status remains what it has been for the last two decades: no finished-drug approval, no active Investigational New Drug (IND) application, and no FDA-registered human clinical trials
External resources Triple-Hormone-Receptor Agonist Retatrutide for Obesity, Phase 2 Trial (NEJM) Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1 (NEJM) Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease (Nature Medicine) In case I do not see you, good afternoon, good evening, and good night
